Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma

被引：4

作者：

Acosta, M ^{[1
]}

Teitelbaum, A ^{[1
]}

机构：

[1] Ligand Pharmaceut Inc, San Diego, CA 92121 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2001年 / 44卷 / 02期

关键词：

D O I：

10.1067/mjd.2001.110643

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：312 / 313

页数：2

共 7 条

[1] Vascular leak syndrome: a side effect of immunotherapy [J].

Baluna, R ;

Vitetta, ES .

IMMUNOPHARMACOLOGY, 1997, 37 (2-3) :117-132

[2] Phase I trial of an Anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration [J].

Conry, RM ;

Khazaeli, MB ;

Saleh, MN ;

Ghetie, V ;

Vitetta, ES ;

Liu, TP ;

LoBuglio, AF .

JOURNAL OF IMMUNOTHERAPY, 1995, 18 (04) :231-241

[3]

Foss F, 1999, BLOOD, V94, p98A

[4]

Frankel AE, 2000, CLIN CANCER RES, V6, P326

[5]

Frankel AE, 1999, BLOOD, V94, p229B

[6]

RAILAN, 2000, J AM ACAD DERMATOL, V43, P323

[7] PREVENTION OF IMMUNOTOXIN-MEDIATED VASCULAR LEAK SYNDROME IN RATS WITH RETENTION OF ANTITUMOR-ACTIVITY [J].

SIEGALL, CB ;

LIGGITT, D ;

CHACE, D ;

TEPPER, MA ;

FELL, HP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (20) :9514-9518

← 1 →